Peer-Supported Stand Down for Alcoholism

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, CA
Alcoholism
Peer-Supported Stand Down - Behavioral
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

Hazardous drinking is common among Veteran primary care patients and increases risk for more costly and complex medical problems over the long-term. Yet, the vast majority of these Veterans go untreated. By providing an option for care that is easily accessible, private, and self-directed, mobile applications (apps) circumvent many barriers to alcohol use treatment. However, poor patient engagement remains the Achilles' heel of these apps. Through supportive accountability, Peer Specialists can maximize the reach and engagement of these apps with patients and improve drinking outcomes. The goal of this project is to evaluate whether an app for alcohol use self-management ("Stand Down") reduces drinking among Veteran primary care patients who engage in hazardous drinking, and for whom Peer-Supported-Stand Down is more effective than the app alone. If successful, the proposed research has the potential to transform care and increase access to alcohol-related services for Veterans who engage in hazardous drinking but rarely seek treatment, and, in turn, mitigate the adverse health outcomes that stem from untreated hazardous drinking.

Treatment Effectiveness

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: 32 weeks post-baseline

32 weeks post-baseline
Drinks Per Drinking Day (DPDD)
Heavy Drinking Days (HDD)
Negative Consequences from Drinking
Percent Days Abstinent (PDA)
Readiness to Change Drinking
Self-Efficacy to Reduce Drinking
Total standard drinks

Trial Safety

Trial Design

3 Treatment Groups

Usual Care
1 of 3
UC + Stand Down app (app only)
1 of 3
UC + Peer-Supported Stand Down (PS-Stand Down)
1 of 3
Active Control
Experimental Treatment

274 Total Participants · 3 Treatment Groups

Primary Treatment: Peer-Supported Stand Down · No Placebo Group · N/A

UC + Stand Down app (app only)Experimental Group · 2 Interventions: Peer-Supported Stand Down, Stand Down app · Intervention Types: Behavioral, Behavioral
UC + Peer-Supported Stand Down (PS-Stand Down)
Behavioral
Experimental Group · 1 Intervention: Peer-Supported Stand Down · Intervention Types: Behavioral
Usual CareActiveComparator Group · 3 Interventions: Peer-Supported Stand Down, Stand Down app, Usual Care · Intervention Types: Behavioral, Behavioral, Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 32 weeks post-baseline
Closest Location: VA Palo Alto Health Care System, Palo Alto, CA · Palo Alto, CA
Photo of california 1Photo of california 2Photo of california 3
2006First Recorded Clinical Trial
6 TrialsResearching Alcoholism
53 CompletedClinical Trials

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,459 Previous Clinical Trials
2,748,639 Total Patients Enrolled
40 Trials studying Alcoholism
6,226 Patients Enrolled for Alcoholism
Daniel M. Blonigen, PhD MAPrincipal InvestigatorVA Palo Alto Health Care System, Palo Alto, CA
3 Previous Clinical Trials
790 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
A positive AUDIT-C score indicates a pattern of alcohol use that is consistent with an alcohol use disorder.
You have received a positive screen for a urinary tract infection.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.